Scienture Q3 Revenue Jumps 113% to $1.25M as REZENOPY Launch Delivers $925K
SCNX is trading near its 52-week low of $2.64 (14% above the low).
Summary
Scienture reported Q3 2026 revenue of $1.25M, up about 113% year over year and roughly 265% sequentially, confirming the preliminary ~$1.22M figure it released on October 13. The August launch of REZENOPY drove about $925K of net product revenue, with the rest coming from Arbli and related products. Gross profit was $1.02M, up about 77.5% year over year, so profit grew slower than sales. Nine-month revenue reached $1.65M, up about 176%. Management says it is targeting profitability in 2027, but that is an objective, not guidance, and the release flags dependence on wholesaler ordering patterns that can swing quarterly revenue. The company is still very small — this is an early commercial-stage story where repeat REZENOPY orders and broader distribution decide whether the growth holds.
Updates
· SEC 8-K — Scienture's Q3 2026 gross margin was about 81.3%, and it held $7.8M in cash and restricted cash as of September 30, 2026.
At the time of this announcement, SCNX was trading at $3.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $2.64 to $18.75. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.